Investment Stage

Focus Areas

About Investor

Pedro Bueno is a Partner at DNA Capital who focuses on investments in Medical Devices, Consumer Health, Pharmaceuticals, BioTech, Health & Hospital Services, Health IT, and Digital Health across various stages including Pre-seed, Seed, Series A, and Series B, with investment ranges typically between $100K and $5.0M. His verified work background includes beginning his career in investment banking at BTG Pactual where he worked on multiple M&A transactions. In 2012, he joined Amil and participated in the sale of the company to UnitedHealth Group, which was the largest investment ever made by a North American group in Brazil at the time. Bueno subsequently joined DASA as its CEO and is currently the CEO of the combined company formed by the merger of DASA (5th largest diagnostics company in the world) and Rede Ímpar (2nd largest Brazilian independent hospital chain), as well as a board member of both companies.